https://scholars.lib.ntu.edu.tw/handle/123456789/579794
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Lee Y.-L. | en_US |
dc.contributor.author | KUAN-YIN LIN | en_US |
dc.contributor.author | Cheng S.-H. | en_US |
dc.contributor.author | Lu P.-L. | en_US |
dc.contributor.author | Wang N.-C. | en_US |
dc.contributor.author | Ho M.-W. | en_US |
dc.contributor.author | Yang C.-J. | en_US |
dc.contributor.author | Liou B.-H. | en_US |
dc.contributor.author | Tang H.-J. | en_US |
dc.contributor.author | Huang S.-S. | en_US |
dc.contributor.author | Huang S.-H. | en_US |
dc.contributor.author | Chen T.-C. | en_US |
dc.contributor.author | Lin C.-Y. | en_US |
dc.contributor.author | Lin S.-P. | en_US |
dc.contributor.author | Lee Y.-T. | en_US |
dc.contributor.author | CHIEN-CHING HUNG | en_US |
dc.contributor.author | Taiwan HIV Study Group | en_US |
dc.date.accessioned | 2021-08-27T06:48:46Z | - |
dc.date.available | 2021-08-27T06:48:46Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0924-8579 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111970673&doi=10.1016%2fj.ijantimicag.2021.106403&partnerID=40&md5=403d5ec5432ddbf9cce8e88921ebae30 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/579794 | - |
dc.description.abstract | Real-world experience with dolutegravir (DTG) plus boosted protease inhibitor (bPI) as a two-drug regimen is limited for highly experienced HIV-positive patients with virological failure or intolerance to antiretroviral therapy. Patients receiving DTG plu | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.ispartof | International Journal of Antimicrobial Agents | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | dolutegravir; proteinase inhibitor; antiretrovirus agent; dipyrone; fused heterocyclic rings; integrase inhibitor; oxazine derivative; piperazine derivative; adult; antiretroviral therapy; antiviral resistance; Article; body weight gain; combination drug | - |
dc.title | Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.ijantimicag.2021.106403 | - |
dc.identifier.pmid | 34289404 | - |
dc.identifier.scopus | 2-s2.0-85111970673 | - |
dc.relation.pages | 106403 | - |
dc.relation.journalvolume | 58 | - |
dc.relation.journalissue | 3 | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Tropical Medicine and Parasitology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-6877-5345 | - |
crisitem.author.orcid | 0000-0001-7345-0836 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。